Mizuho's Holtz talks what is behind Novo's bid for Metsera

Here's a summary of the YouTube video transcript, maintaining the original language and technical precision:

Key Concepts

• Eli Lilly: Pharmaceutical company experiencing significant growth driven by GLP-1 drugs.
• Novo Nordisk: Pharmaceutical company making an unsolicited bid for Metsera.
• Zepbound & Mounjaro: Eli Lilly's GLP-1 drugs for obesity and diabetes, respectively, driving company revenue.
• Metsera: A company that Novo Nordisk is attempting to acquire.
• GLP-1 Drugs: A class of drugs, including Mounjaro and Zepbound, used for diabetes and weight management, experiencing booming demand.
• Unsolicited Bid: A takeover offer made directly to a company's shareholders, bypassing the board.
• Risk Arbitrage (Risk Arb): A trading strategy that seeks to profit from price discrepancies in related securities, often involved in mergers and acquisitions.
• FTC (Federal Trade Commission): A U.S. government agency responsible for consumer protection and antitrust enforcement.
• Drug Pricing: Political and regulatory discussions surrounding the cost of pharmaceuticals.
• Manufacturing: The process of producing drugs, with companies considering bringing it back domestically to mitigate risks.
• Pipeline: A company's portfolio of drug candidates in various stages of development.
• Catalyst: An event or development that is expected to significantly impact a company's stock price, such as clinical trial readouts.

Eli Lilly's Earnings and GLP-1 Demand

Eli Lilly reported a strong earnings report, with its stock surging nearly 4%. This performance is attributed to the booming demand for its GLP-1 drugs, Zepbound and Mounjaro. Mounjaro and Zepbound collectively generated $10 billion in revenue for Eli Lilly, which reported a total of $17 billion in revenue. A notable aspect of Eli Lilly's growth is that a significant portion of Mounjaro's demand originated from outside the United States, indicating strong international market penetration. The company raised its guidance by $2 billion, signaling high confidence for the remaining two months of the year. The transcript notes that predicting prescription data for these drugs is becoming more challenging for analysts due to its wide availability, making it difficult to "beat" those numbers.

Novo Nordisk's Unsolicited Bid for Metsera

Novo Nordisk has made an unsolicited bid to acquire Metsera, reportedly a better offer than the one previously made by Pfizer. This move is described as "out of character" for Novo Nordisk and is interpreted by healthcare strategist Jared Holles as a sign of "desperation." This desperation is seen across the board, with Pfizer having "missed the boat" on certain opportunities and Novo Nordisk's pipeline facing hits.

Key Arguments and Perspectives on Novo Nordisk's Bid:

• Desperation: Holles argues that the bid reflects a degree of desperation, particularly given Pfizer's perceived missteps and Novo Nordisk's pipeline challenges.
• Aggression: The bid could also be interpreted as an aggressive move to turn the business around.
• Unusual Structure: The deal structure is noted as unusual, with the risk arb community observing a method that appears to circumvent the FTC. This raises significant legalities.
• Metsera's Previous Decision: Metsera had previously chosen not to accept Novo Nordisk's deal, believing it wouldn't go through. Their current consideration suggests a belief that the deal might now be viable.
• New Leadership: The transcript mentions that Novo Nordisk has new board members, including a former head of R&D at Pfizer, which could influence strategic decisions.

Urgency and Metsera's Upcoming Readouts

There is an anticipated rush to get the Metsera deal finalized or worked on before Metsera's key clinical readouts scheduled for December and January. As a buyer, Novo Nordisk would ideally want to acquire the asset before these potentially positive catalysts can further increase Metsera's stock price.

Political Landscape and Drug Pricing for GLP-1s

Eli Lilly's significant success with Mounjaro and Zepbound has made them a potential "victim of their own success" in the political landscape. The U.S. administration has discussed drug pricing and specifically singled out GLP-1s as a class that needs control. This has led companies to consider bringing manufacturing back to the U.S. to mitigate such risks. The transcript also highlights a significant price decrease for these drugs within a year, with prices falling by 50% from around $1,200 a month to $400-$500 a month.

Other Potential Acquisition Targets

In the context of the race for Metsera, other companies being considered in the market include:

• Amylin: Mentioned for its structure and potential value, with a drug expected to enter the clinic in the next one to two months.
• Viking: Still considered a potential target, though manufacturing capacity has been a gating factor. The transcript suggests that while the asset might be acquirable, significant investment in manufacturing infrastructure would be required, making Metsera a potentially "easier lift" for large-cap pharmaceutical strategics.

Conclusion

The transcript highlights a dynamic pharmaceutical market driven by the immense success of GLP-1 drugs. Eli Lilly is capitalizing on this demand, while Novo Nordisk is making aggressive, potentially desperate moves to acquire Metsera, navigating complex deal structures and regulatory scrutiny. The political climate surrounding drug pricing and the upcoming clinical catalysts for companies like Metsera add further layers of complexity and urgency to these M&A activities. The market is also watching other potential targets like Amylin and Viking, though manufacturing challenges remain a key consideration.